(A joint stock limited liability company incorporated in the People's Republic of China)
Stock code: 2120

Contents

Corporate Information

Executive Directors

Non-executive Directors

Independent Non-executive Directors

Audit Committee

Nomination Committee

Remuneration Committee

Strategy and Risk Management Committee

Supervisory Committee

Joint Company Secretaries

Authorized Representatives

Auditor

Corporate Information

Financial Highlights

	For the year ended December 31,				
	2018	[illegible]	[illegible]	[illegible]	[illegible]
	RMB'000	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	745,972	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	106,910	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	(31,941)	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	74,969	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	80,596	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	(5,627)	[illegible]	[illegible]	[illegible]	[illegible]

	As of December 31,				
	2018	[illegible]	[illegible]	[illegible]	[illegible]
	RMB'000	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	1,840,724	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	635,451	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	1,205,273	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	1,120,995	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	84,278	[illegible]	[illegible]	[illegible]	[illegible]

Chairman's Statement

Chairman's Statement (Continued)

GUAN Weili

Management Discussion and Analysis

Psychiatric Specialized Medical Service Industry in China

Management Discussion and Analysis

Management Discussion and Analysis

Management Discussion and Analysis

Business Outlook

( )

% % %

( )

( )

Management Discussion and Analysis

Financial Review

[illegible]

Revenue and Cost of Revenue

[illegible]

[illegible]

	For the year ended December 31,	
	2018	[illegible]
	(RMB'000)	[illegible]
[illegible]	706,651	[illegible]
[illegible]	19,748	[illegible]
[illegible]	726,399	[illegible]
[illegible]	2,533	[illegible]
[illegible]	17,040	[illegible]
Total revenue	745,972	[illegible]

Management Discussion and Analysis

	For the year ended December 31,	
	2018	[illegible]
	(RMB'000)	[illegible]
Treatment and general healthcare services		
[illegible]	539,548	[illegible]
[illegible]	331,883	[illegible]
[illegible]	207,665	[illegible]
Pharmaceutical sales		
[illegible]	167,103	[illegible]
[illegible]	140,330	[illegible]
[illegible]	26,773	[illegible]
Owned hospitals		
[illegible]	706,651	[illegible]
[illegible]	472,213	[illegible]
[illegible]	234,438	[illegible]

Management Discussion and Analysis

[illegible]

[illegible]

[illegible]

	For the year ended December 31, 2018 (RMB'000)	[illegible]
[illegible]	177,106	[illegible]
[illegible]	158,047	[illegible]
[illegible]	27,938	[illegible]
[illegible]	45,222	[illegible]
[illegible]	25,331	[illegible]
[illegible]	14,093	[illegible]
[illegible]	24,476	[illegible]
Cost of revenue of owned hospitals	472,213	[illegible]

[illegible]

Management Discussion and Analysis

[illegible]

[illegible]

[illegible]

	For the year ended December 31,	
	2018	[illegible]
	(RMB'000)	[illegible]
[illegible]	19,748	[illegible]
[illegible]	12,816	[illegible]
[illegible]	6,932	[illegible]

[illegible]

[illegible]

Management Discussion and Analysis

Management Discussion and Analysis

Selling Expenses

[illegible]

Administrative Expenses

[illegible]

	For the year ended December 31,	
	2018	[illegible]
	(RMB'000)	[illegible]
[illegible]	55,281	[illegible]
[illegible]	4,095	[illegible]
[illegible]	8,723	[illegible]
[illegible]	10,218	[illegible]
[illegible]	3,694	[illegible]
[illegible]	15,990	[illegible]
Total administrative expenses	98,001	[illegible]

[illegible]

Research and Development Expenses

[illegible]

Management Discussion and Analysis

Finance Expenses – Net

[illegible]

	For the year ended December 31,	
	2018	[illegible]
	(RMB'000)	[illegible]
[illegible]	3,683	[illegible]
[illegible]	4,074	[illegible]
[illegible]	(8,850)	[illegible]
[illegible]	(5,511)	[illegible]
[illegible]	(567)	[illegible]
Finance expenses – net	(7,171)	[illegible]

[illegible]

Investment Losses

[illegible]

	For the year ended December 31,	
	2018	[illegible]
	(RMB'000)	[illegible]
[illegible]	(10,029)	[illegible]
[illegible]	1,727	[illegible]
	(8,302)	[illegible]

[illegible]

Management Discussion and Analysis

Assets Impairment Losses and Credit Impairment Losses

[illegible]

Non-Operating Income (Expenses) and Other Gains

[illegible]

	For the year ended December 31,	
	2018	[illegible]
	(RMB'000)	[illegible]
[illegible]	6,714	[illegible]
[illegible]	468	[illegible]
Non-operating income	7,182	[illegible]
[illegible]	—	[illegible]
[illegible]	5,254	[illegible]
[illegible]	788	[illegible]
Non-operating expenses	6,042	[illegible]
Other gains	8,538	[illegible]

[illegible]

Income Tax Expense

[illegible]

Management Discussion and Analysis

Total Comprehensive Income

[illegible]

	For the year ended December 31,	
	2018	[illegible]
	(RMB'000)	[illegible]
[illegible]	4,074	[illegible]
[illegible]	—	[illegible]
[illegible]	(2,755)	[illegible]
Total impact of non-recurring items (before income tax)	1,319	[illegible]
Total impact of non-recurring items (after income tax)	60	[illegible]

[illegible]

Management Discussion and Analysis

Inventory

%

%

Accounts Receivables

%

Other Receivables and Prepayments

Management Discussion and Analysis

Investment Properties

Other Non-current Financial Assets

Management Discussion and Analysis

Net Cash Generated from Financing Activities

Significant Investment, Acquisition and Disposal

Bank Borrowings

Contingent Liabilities

Asset Pledge

Contractual Obligations

Financial Instruments

Management Discussion and Analysis

Exposure to Fluctuation in Exchange Rates

Gearing Ratio

%

%

Employees and Remuneration Policy

Equity Incentive Scheme

2017 AGM

Management Discussion and Analysis

[illegible]

Category of personnel	Number of persons granted (person)	Number of Shares granted (Share)	Number of grant representing total issued share capital of the Company
[illegible]	4	[illegible]	[illegible]%
[illegible]	161	[illegible]	[illegible]%
[illegible]	165	[illegible]	[illegible]%

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Report of the Board

Report of the Board

(《中華人民共和國精神衛生法》)

(《醫療機構管理條例》)

(《醫療機構管理條例實施細則》)

Report of the Board

[illegible]

The use of net proceeds set out in the Prospectus	Original allocation of net proceeds Approximate (RMB million)	Approximate (%)	Amount of net proceeds used as of December 31, 2018 Approximate (RMB million)	Approximate (%)	Remaining net proceeds as of December 31, 2018 Approximate (RMB million)	Approximate (%)
[illegible]	[illegible]		[illegible]		[illegible]	[illegible]
[illegible]	[illegible]		[illegible]	[illegible]		
[illegible]	[illegible]	[illegible]	[illegible]			
[illegible]	[illegible]		[illegible]		[illegible]	[illegible]
[illegible]	[illegible]		[illegible]			
Total	580.7	100.0	541.1	100.0	37.9	100.0

Report of the Board

（ Record Date ）

（《中華人民共和國企業所得稅法》）

%

Report of the Board

Report of the Board

Report of the Board

Report of the Board

Executive Directors

Non-executive Directors

Independent Non-executive Directors

Report of the Board

[illegible]

Report of the Board

[illegible]

[illegible] % [illegible]

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class[1]	Approximate Percentage of the Company's Total Issued Share Capital[1]
[illegible] ("Defu Fund") (廣州德福股權投資基金合夥企業（有限合夥）（「德福基金」）)	[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]%
[illegible] (廣州德福投資諮詢合夥企業（有限合夥）) [illegible]	[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]%
[illegible] (廣汽資本有限公司) [illegible]	[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]%
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]%
[illegible] (上海檀英投資合夥企業（有限合夥）)	[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]%
[illegible] (上海樂進投資合夥企業（有限合夥）) [illegible]	[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]%
[illegible] (上海乾剛投資管理合夥企業（有限合夥）)	[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]%
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]%
[illegible] (上海盛歌投資管理有限公司) [illegible]	[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]%
[illegible] (青島金石灝汭投資有限公司)	[illegible]	[illegible]	[illegible]	[illegible]%	[illegible]%

Report of the Board

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class[1]	Approximate Percentage of the Company's Total Issued Share Capital[1]
[illegible] （金石投資有限公司）[illegible] Company [illegible]	[illegible]	[illegible]	[illegible] 0,000 (L) [illegible]	[illegible] %	[illegible] %

Report of the Board

( ) [illegible] (上海樂進投資合夥企業(有限合夥)) [illegible] % [illegible] (上海檀英投資合夥企業(有限合夥)) [illegible] (上海樂進投資合夥企業(有限合夥)) [illegible] (上海檀英投資合夥企業(有限合夥)) [illegible]

( ) [illegible] % [illegible] (上海乾剛投資管理合夥企業(有限合夥)) [illegible] (上海乾剛投資管理合夥企業(有限合夥)) [illegible]

( ) [illegible] (上海盛歌投資管理有限公司) [illegible] (上海乾剛投資管理合夥企業(有限合夥)) [illegible] (上海檀英投資合夥企業(有限合夥)) [illegible] (上海盛歌投資管理有限公司) [illegible] (上海乾剛投資管理合夥企業(有限合夥)) [illegible] (上海檀英投資合夥企業(有限合夥)) [illegible]

( ) [illegible] (青島金石灝汭投資有限公司) [illegible] (金石投資有限公司) [illegible] (金石投資有限公司) [illegible] (青島金石灝汭投資有限公司) [illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Report of the Board

For determining the entitlement to attend and vote at the AGM

For determining the entitlement to the Proposed Final Dividendof the Register of Members’

Report of the Board

GUAN Weili

Report of the Supervisory Committee

SUN Fangjun

Board Composition

Corporate Governance Report

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Corporate Governance Report

Accounting Policies

Adoption of New Accounting Policies

Corporate Governance Report

Impact of Change in the Format of Financial Statements

[illegible]

[illegible]

Corporate Governance Report

Directors	Number of meetings convened/attended
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]

Directors	Number of meetings convened/attended
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]

Corporate Governance Report

Directors	Number of meetings convened/attended
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]

Corporate Governance Report

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Corporate Governance Report

Remuneration band (RMB)	Number of individuals
[illegible]	[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Corporate Governance Report

Procedures for Shareholder(s) to Convene an Extraordinary General Meeting ("EGM")

Procedures for Shareholder(s) to Put Forward Proposals at a General Meeting

[illegible]

Procedures for Directing Shareholders' Enquiries to the Board

[illegible]

Directors, Supervisors and Senior Management

Executive Directors

Mr. GUAN Weili（管偉立）

（溫州市精神病院）

（溫州醫科大學）

（溫州醫學院）

（溫州市人事局）

Ms. WANG Lianyue（王蓮月）

（溫州市精神病院）

（中共溫州市委黨校）

（西安交通大學網絡教育學院）

（中歐國際工商學院）

（二級心理諮詢師）

（人力資源和社會保障部）

Directors, Supervisors and Senior Management

Ms. WANG Hongyue (王紅月)

(溫州市龍灣區康寧醫藥批發公司)

(西安交通大學網絡教育學院)

Non-executive Directors

Mr. YANG Yang (楊揚)

(長立實業有限公司)

(中國人民解放軍海軍學院)

Directors, Supervisors and Senior Management

Mr. LIN Lijun (林利軍)

Independent Non-executive Directors

Mr. CHONG Yat Keung (莊一強)

(中國醫院協會)

(廣州艾力彼管理顧問有限公司)

(阿斯利康(中國))

(北京諾華製藥有限公司)

(中山大學)

Directors, Supervisors and Senior Management

Mr. HUANG Zhi（黃智）[illegible]（安徽開潤股份有限公司）[illegible]（武漢東湖高新集團股份有限公司）[illegible]（西藏天路股份有限公司）[illegible]（上海信公企業管理諮詢有限公司）[illegible]（自貢華氣科技股份有限公司）[illegible]（天風證券股份有限公司）[illegible]（復旦大學）[illegible]（中國註冊會計師協會）[illegible]

Directors, Supervisors and Senior Management

Mr. GOT Chong Key Clevin (葛創基) [illegible] (香港乳癌基金會) [illegible] (東華三院) [illegible] & [illegible] (香港森那美集團夏巴公司) [illegible] (大昌行集團有限公司) [illegible] (麥基大學) [illegible]

Mr. SUN Fangjun (孫方俊) [illegible] (溫州市鹿城區衛生局) [illegible] (溫州市紅旗醫院) [illegible] (溫州市第八人民醫院) [illegible] (黑龍江省雞西衛校) [illegible] (溫州市人事局) [illegible]

Directors, Supervisors and Senior Management

Ms. HUANG Jingou (黃靖歐) [illegible] (德福資本) [illegible] (美國中華醫學基金會) [illegible] & [illegible] (胡關李羅律師行) [illegible] (中山大學) [illegible]

Mr. MA Jinlong (馬津龍) [illegible] & [illegible] (寧夏平羅農村商業銀行股份有限公司) [illegible] (瑞安農村商業合作銀行) [illegible] (浙江蒼南農村合作銀行) [illegible]

Directors, Supervisors and Senior Management

Mr. QIAN Chengliang (錢成良) [illegible]

Mr. XIE Tiefan (謝鐵凡) [illegible] (中央廣播電視大學) [illegible] (溫州市人事局) [illegible]

[illegible]

Mr. WANG Qian (王 謙) [illegible] (溫州市人民醫院) [illegible] (泰順縣人民醫院) [illegible] (溫州醫科大學) [illegible] (溫州醫學院) [illegible] (浙江省人力資源和社會保障廳) [illegible]

Directors, Supervisors and Senior Management

Mr. ZHOU Chaoyi（周朝毅）[illegible]（溫州心血管醫院）[illegible]（科長）[illegible]（溫州市中醫院）[illegible]（溫州市氣功療養院）[illegible]（高級研修班）[illegible]（溫州市衛生局）[illegible]（浙江省衛生廳）[illegible]

Mr. YE Minjie（葉敏捷）[illegible]（科長）[illegible]（溫州市精神病院）[illegible]（新鄉醫學院）[illegible]（浙江省人力資源和社會保障廳）[illegible]

Directors, Supervisors and Senior Management

Mr. XU Yi (徐誼) (科长) (中共溫州市委黨校) (北京經濟管理職業學院)

Ms. ZHANG Feixue (章飛雪)

Directors, Supervisors and Senior Management

Mr. WANG Jian (王健) [illegible] (科員) [illegible] (副主任科員) [illegible] (中國證監會廈門監管局) [illegible] & [illegible] (安永華明會計師事務所(特殊普通合夥)) [illegible] (註冊會計師非執業會員) [illegible]

Mr. JIN Weiguang (金偉光) [illegible]

Directors, Supervisors and Senior Management

Directors/ Senior Management	Members of the Group	Positions Held at

Directors, Supervisors and Senior Management

Directors/ Senior Management	Members of the Group	Positions Held at Members of the Group	Term of Office
[illegible]	[illegible]	[illegible]	[illegible]

Executiv393

Directors, Supervisors and Senior Management

Directors/ Senior Management	Members of the Group	Positions Held at Members of the Group	Term of Office
[illegible]	[illegible]	[illegible]	[illegible]

Directors, Supervisors and Senior Management

Directors/ Senior Management	Members of the Group	Positions Held at Members of the Group	Term of Office
[illegible]	[illegible]	[illegible]	[illegible]
	[illegible]	[illegible]	[illegible]
	[illegible]		
[illegible]	[illegible]	[illegible]	[illegible]
	[illegible]	[illegible]	[illegible]
	[illegible]	[illegible]	[illegible]
	[illegible]	[illegible]	[illegible]
	[illegible]		
	[illegible]	[illegible]	[illegible]
	[illegible]		
	[illegible]	[illegible]	[illegible]
	[illegible]	[illegible]	[illegible]
	[illegible]	[illegible]	[illegible]
	[illegible]		
[illegible]	[illegible]	[illegible]	[illegible]
		[illegible]	

Auditor’s Report

To the Shareholders of Wenzhou Kangning Hospital Co., Ltd.,

What we have audited

Auditor's Report

Auditor's Report

Auditor's Report

Auditor's Report

Consolidated Balance Sheet

[illegible]

[illegible]

ASSETS	[illegible]	31 December 2018	[illegible]	[illegible]
Current assets				
[illegible]	[illegible]	187,076,694	[illegible]	[illegible]
[illegible]	[illegible]	299,750,063	[illegible]	[illegible]
[illegible]	[illegible]	58,051,581	[illegible]	[illegible]
[illegible]	[illegible]	16,683,839	[illegible]	[illegible]
[illegible]	[illegible]	20,813,747	[illegible]	[illegible]
[illegible]	[illegible]	12,688,704	[illegible]	[illegible]
Total current assets		595,064,628	[illegible]	[illegible]
Non-current assets				
[illegible]	[illegible]	NA		
[illegible]	[illegible]	50,974,323	[illegible]	[illegible]
[illegible]	[illegible]	100,321,983	[illegible]	[illegible]
[illegible]	[illegible]	128,568,963	[illegible]	[illegible]
[illegible]	[illegible]	444,322,834	[illegible]	[illegible]
[illegible]	[illegible]	131,187,406	[illegible]	[illegible]
[illegible]	[illegible]	185,257,977	[illegible]	[illegible]
[illegible]	[illegible]	19,296,005	[illegible]	[illegible]
[illegible]	[illegible]	144,386,669	[illegible]	[illegible]
[illegible]	[illegible]	33,825,347	[illegible]	[illegible]
[illegible]	[illegible]	7,517,900	[illegible]	[illegible]
Total non-current assets		1,245,659,407	[illegible]	[illegible]
TOTAL ASSETS		1,840,724,035	[illegible]	[illegible]

Consolidated Balance Sheet

[illegible]

LIABILITIES AND OWNERS' EQUITY	[illegible]	31 December 2018	[illegible]	[illegible]
Current liabilities				
[illegible]	[illegible]	145,000,000	[illegible]	[illegible]
[illegible]	[illegible]	73,644,717	[illegible]	[illegible]
[illegible]	[illegible]	—	[illegible]	[illegible]
[illegible]	[illegible]	2,244,706	[illegible]	[illegible]
[illegible]	[illegible]	28,270,410	[illegible]	[illegible]
[illegible]	[illegible]	41,119,676	[illegible]	[illegible]
[illegible]	[illegible]	129,807,988	[illegible]	[illegible]
[illegible]	[illegible]	63,757,304	[illegible]	[illegible]
Total current liabilities		483,844,801	[illegible]	[illegible]
Non-current liabilities				
[illegible]	[illegible]	40,000,000	[illegible]	[illegible]
[illegible]	[illegible]	86,645,200	[illegible]	[illegible]
[illegible]	[illegible]	10,253,059	[illegible]	[illegible]
[illegible]	[illegible]	14,707,619	[illegible]	[illegible]
Total non-current liabilities		151,605,878	[illegible]	[illegible]
Total liabilities		635,450,679	[illegible]	[illegible]
Owners' equity				
[illegible]	[illegible]	75,500,000	[illegible]	[illegible]
[illegible]	[illegible]	827,379,886	[illegible]	[illegible]
[illegible]	[illegible]	(21,910,000)		
[illegible]	[illegible]	29,981,034	[illegible]	[illegible]
[illegible]	[illegible]	210,044,608	[illegible]	[illegible]
Total equity attributable to owners of the parent company		1,120,995,528	[illegible]	[illegible]
Non-controlling interests		84,277,828	[illegible]	[illegible]
Total owners' equity		1,205,273,356	[illegible]	[illegible]
TOTAL LIABILITIES AND OWNERS' EQUITY		1,840,724,035	[illegible]	[illegible]

[illegible]

[illegible]	[illegible]	[illegible]
GUAN Weili	WANG Hongyue	XU Qunyan

Balance Sheet

[illegible]

ASSETS	[illegible]	31 December 2018	[illegible]	[illegible]
Current assets				
[illegible]		147,680,587	[illegible]	[illegible]
[illegible]	[illegible]	108,177,162	[illegible]	[illegible]
[illegible]		3,882,154	[illegible]	[illegible]
[illegible]	[illegible]	554,772,707	[illegible]	[illegible]
[illegible]		8,404,245	[illegible]	[illegible]
[illegible]		12,688,704	[illegible]	[illegible]
Total current assets		835,605,559	[illegible]	[illegible]
Non-current assets				
[illegible]	[illegible]	NA		
[illegible]	[illegible]	50,974,323	[illegible]	[illegible]
[illegible]	[illegible]	172,804,786	[illegible]	[illegible]
[illegible]	[illegible]	319,978,975	[illegible]	[illegible]
[illegible]	[illegible]	4,508,592	[illegible]	[illegible]
[illegible]	[illegible]	96,340,865	[illegible]	[illegible]
[illegible]		18,656,548	[illegible]	[illegible]
[illegible]		171,000		[illegible]
[illegible]		7,665,855	[illegible]	[illegible]
Total non-current assets		671,100,944	[illegible]	[illegible]
TOTAL ASSETS		1,506,706,503	[illegible]	[illegible]

Balance Sheet

[illegible]

LIABILITIES AND OWNERS' EQUITY	[illegible]	31 December 2018	[illegible]	[illegible]
Current liabilities				
[illegible]		105,000,000		[illegible]
[illegible]		24,081,460	[illegible]	[illegible]
[illegible]		—	[illegible]	[illegible]
[illegible]		779,733	[illegible]	[illegible]
[illegible]		13,395,856	[illegible]	[illegible]
[illegible]		10,129,626	[illegible]	[illegible]
[illegible]		57,248,249	[illegible]	[illegible]
[illegible]		63,757,304	[illegible]	[illegible]
Total current liabilities		274,392,228	[illegible]	[illegible]
Non-current liabilities				
[illegible]		40,000,000	[illegible]	[illegible]
[illegible]		86,645,200	[illegible]	[illegible]
[illegible]		10,253,059	[illegible]	[illegible]
Total non-current liabilities		136,898,259	[illegible]	[illegible]
Total liabilities		411,290,487	[illegible]	[illegible]
Owners' equity				
[illegible]	[illegible]	75,500,000	[illegible]	[illegible]
[illegible]	[illegible]	828,931,889	[illegible]	[illegible]
[illegible]	[illegible]	(21,910,000)		
[illegible]		29,981,034	[illegible]	[illegible]
[illegible]	[illegible]	182,913,093	[illegible]	[illegible]
Total owners' equity		1,095,416,016	[illegible]	[illegible]
TOTAL LIABILITIES AND OWNERS' EQUITY		1,506,706,503	[illegible]	[illegible]

[illegible]

[illegible] [illegible] [illegible]

Consolidated Income Statement

Item		Year Ended 31 December 2018	
1. Revenue		745,971,888	
		(493,729,636)	
		(5,720,201)	
		(5,141,918)	
		(98,001,249)	
		(5,733,120)	
		(7,171,247)	
		(4,823,557)	
		(18,695,980)	
		8,538,235	
		(8,302,493)	
		(10,029,269)	
		(1,420,551)	
2. Operating profit		105,770,171	
		7,182,072	
		(6,041,975)	
3. Total profit		106,910,268	
		(31,941,040)	
4. Net profit		74,969,228	
		74,969,228	
		—	
		80,595,677	
		(5,626,449)	
5. Total comprehensive income		74,969,228	
		80,595,677	
		(5,626,449)	
6. Earnings per share			
		1.10	
		1.09	

Income Statement

[illegible]

Item	[illegible]	Year Ended 31 December 2018	[illegible]
1. Revenue	[illegible]	354,166,839	[illegible]
[illegible]	[illegible]	(230,191,852)	[illegible]
[illegible]		(2,957,704)	[illegible]
[illegible]	[illegible]	(1,797,984)	[illegible]
[illegible]	[illegible]	(51,747,365)	[illegible]
[illegible]	[illegible]	(5,733,120)	[illegible]
[illegible]	[illegible]	(5,198,109)	[illegible]
[illegible]		—	[illegible]
[illegible]	[illegible]	(4,921,160)	[illegible]
[illegible]		4,213,299	[illegible]
[illegible]	[illegible]	17,800,908	[illegible]
[illegible]		(1,479,145)	[illegible]
2. Operating profit		72,154,607	[illegible]
[illegible]		7,339,091	[illegible]
[illegible]		(1,925,819)	[illegible]
3. Total profit		77,567,879	[illegible]
[illegible]	[illegible]	(14,857,659)	[illegible]
4. Net profit		62,710,220	[illegible]
[illegible]			
[illegible]		62,710,220	[illegible]
[illegible]		—	
5. Total comprehensive income		62,710,220	[illegible]

[illegible]

[illegible]

Consolidated Cash Flow Statement

[illegible]

[illegible])

Item	[illegible]	Year Ended 31 December 2018	[illegible]
1. Cash flows from operating activities			
[illegible]		654,660,709	[illegible]
[illegible]		31,999,794	[illegible]
Sub-total of cash inflows		686,660,503	[illegible]
[illegible]		(241,731,386)	([illegible])
[illegible]		(218,086,294)	([illegible])
[illegible]		(39,374,238)	([illegible])
[illegible]		(120,948,057)	([illegible])
Sub-total of cash outflows		(620,139,975)	([illegible])
Net cash flows generated from operating activities	[illegible]) ( )	66,520,528	[illegible]
2. Cash flows from investing activities			
[illegible]		—	
[illegible]		363,629,965	[illegible]
Sub-total of cash inflows		363,629,965	[illegible]
[illegible]		(145,499,984)	([illegible])
[illegible]		(25,190,000)	([illegible])
[illegible]		(17,520,196)	
[illegible]		(330,900,393)	([illegible])
Sub-total of cash outflows		(519,110,573)	([illegible])
Net cash flows used in investing activities		(155,480,608)	([illegible])

Cash Flow Statement

[illegible]
[illegible]

Item	[illegible]	Year Ended 31 December 2018	[illegible]
1. Cash flows used in operating activities			
[illegible]		330,913,867	[illegible]
[illegible]		27,567,019	[illegible]
Sub-total of cash inflows		358,480,886	[illegible]
[illegible]		(129,474,129)	[illegible]
[illegible]		(110,056,158)	[illegible]
[illegible]		(14,606,257)	[illegible]
[illegible]		(157,663,360)	[illegible]
[illegible]		(411,799,904)	[illegible]
Net cash flows used in operating activities		(53,319,018)	[illegible]
2. Cash flows from investing activities			
[illegible]		—	
[illegible]		36,000,000	[illegible]
[illegible]		365,293,712	[illegible]
Sub-total of cash inflows		401,293,712	[illegible]
[illegible]		(40,477,961)	[illegible]
[illegible]		(46,594,921)	[illegible]
[illegible]		(323,091,850)	[illegible]
Sub-total of cash outflows		(410,164,732)	[illegible]
Net cash flows used in investing activities		(8,871,020)	[illegible]

Cash Flow Statement

[illegible]

Item	[illegible]	Year Ended 31 December 2018	[illegible]
3. Cash flows generated from financing activities			
[illegible]		21,910,000	
[illegible]		145,000,000	
[illegible]		166,910,000	
[illegible]		(124,791,600)	([illegible])
[illegible]		(16,108,587)	([illegible])
[illegible]		—	([illegible])
[illegible]		(140,900,187)	([illegible])
Net cash flows generated from/(used in) financing activities		26,009,813	([illegible])
4. Effect of changes in foreign exchange rate		1,113,949	([illegible])
5. Net decrease in cash and cash equivalents		(35,066,276)	([illegible])
[illegible]		184,906,446	[illegible]
6. Cash and cash equivalents at end of the year		149,840,170	[illegible]

[illegible]

[illegible]

Consolidated Statement of Changes in Shareholders's Equity

[illegible]

		Equity attributable to owners of the parent company						
	Note	Share capital	Capital surplus	Less: Treasury Share	Surplus reserve	Retained earnings	Non-controlling interests	Total owners' equity
Balance at 31 December 2017		73,040,000	808,244,186	–	23,710,012	146,840,254	58,662,363	1,110,496,815
[illegible]	2(28)	–	–	–	–	(164,301)	–	(164,301)
Balance at 1 January 2018 (Restated)		73,040,000	808,244,186	–	23,710,012	146,675,953	58,662,363	1,110,332,514
Movements for the year ended 31 December 2018								
[illegible]		–	–	–	–	80,595,677	(5,626,449)	74,969,228
[illegible]		2,460,000	19,450,000	(21,910,000)	–	–	12,910,000	12,910,000
[illegible]	9	–	2,372,415	–	–	–	–	2,372,415
[illegible]	4(29)	–	(3,597,311)	–	–	–	(4,157,192)	(7,754,503)
[illegible]		–	910,596	–	–	–	–	910,596
[illegible]		–	–	–	–	–	22,489,106	22,489,106
[illegible]		–	–	–	6,271,022	(6,271,022)	–	–
[illegible]	4(31)	–	–	–	–	(10,956,000)	–	(10,956,000)
Balance at 31 December 2018		75,500,000	827,379,886	(21,910,000)	29,981,034	210,044,608	84,277,828	1,205,273,356

[illegible]

[illegible]

Consolidated Statement of Changes in Shareholders's Equity

[illegible]

	Note	[illegible]
Balance at 1 January 2017		[illegible]
Movements for the year ended 31 December 2017		
[illegible]	[illegible]	[illegible]
Balance at 31 December 2017		[illegible]

[illegible]

Statement of Changes in Shareholder's Equity

[illegible]

	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Balance at 31 December 2017	[illegible]	[illegible]		[illegible]	[illegible]	[illegible]
[illegible]					[illegible]	[illegible]
Balance at 1 January 2018	[illegible]	[illegible]		[illegible]	[illegible]	[illegible]
Movements for the year ended 31 December 2018						
[illegible]					[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]			
[illegible]		[illegible]				[illegible]
[illegible]				[illegible]	[illegible]	
[illegible]					[illegible]	[illegible]
Balance at 31 December 2018	75,500,000	828,931,889	(21,910,000)	29,981,034	182,913,093	1,095,416,016

[illegible]

[illegible]

Statement of Changes in Shareholder's Equity

	Notes	Share capital	Capital surplus	Surplus reserve	Retained earnings	Total owners' equity
Balance at 1 January 2017		73,040,000	799,821,777	18,548,942	108,895,141	1,000,305,860
Movements for the year ended 31 December 2017						
[illegible]		—	—	—	51,610,704	51,610,704
[illegible]	[illegible]	—	412,805	—	—	412,805
[illegible]		—	6,874,892	—	—	6,874,892
[illegible]						
[illegible]		—	—	5,161,070	(5,161,070)	—
[illegible]	[illegible]	—	—	—	(18,260,000)	(18,260,000)
Balance at 31 December 2017		73,040,000	807,109,474	23,710,012	137,084,775	1,040,944,261

Notes to the Financial Statements

(3) Accounting year

(4) Recording currency

(5) Business combination

(6) Preparation of consolidated financial statements

(6) Preparation of consolidated financial statements

(7) Cash and cash equivalents

Notes to the Financial Statements

(8) Foreign currency translation

(9) Financial instruments

Notes to the Financial Statements

(9) Financial instruments

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

(9) Financial instruments (

Notes to the Financial Statements

(9) Financial instruments (

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

(9) Financial instruments

(10) Inventories

Notes to the Financial Statements

(11) Long-term equity investments

[illegible]

(11) Long-term equity investments ([illegible])

[illegible]

[illegible]

[illegible]

[illegible]

Notes to the Financial Statements

(11) Long-term equity investments

(12) Investment properties

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

[illegible] ([illegible])

(13) Fixed assets

[illegible]

[illegible]

	Estimated useful lives	Estimated net residual values	Annual depreciation rates
Buildings	[illegible]	%	%
Medical equitments	[illegible]	[illegible]%	[illegible]%
Motor vehicles	[illegible]	%	[illegible]%
Electronic and other equipment	[illegible]	[illegible]%	[illegible]%

[illegible]

Notes to the Financial Statements

(13) Fixed assets

(14) Construction in progress

(15) Borrowings costs

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

(16) Intangible assets

	Contractual terms

Notes to the Financial Statements

(16) Intangible assets

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

(17) Long-term prepaid expenses

(18) Impairment of long-term assets

Notes to the Financial Statements

(19) Employee benefits

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(20) Dividend distribution

[illegible]

(21) Share-based payments

(a) [illegible]

[illegible]

[illegible]

(b) [illegible]

[illegible]

(c) [illegible]

[illegible]

Notes to the Financial Statements

(22) Revenue recognition

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

(23) Government grants

Notes to the Financial Statements

(24) Deferred tax assets and deferred tax liabilities

(25) Leases

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

(27) Critical accounting estimates and judgements (

Notes to the Financial Statements

[illegible]

(27) Critical accounting estimates and judgements ([illegible])

[illegible]

[illegible]

	31 December 2018 Fair value	Technical of valuation	Unobservable materially inputs Item	Scope/ Weighted Average	Relationship with the fair value	Observable/ Unobservable
[illegible]	[illegible]	[illegible]	[illegible]	%	( )	[illegible]
			[illegible]	[illegible]		
			[illegible]	%		
[illegible]	[illegible]	[illegible]	[illegible]	%	( )	[illegible]
			[illegible]	[illegible]		

[illegible]

[illegible]

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

(27) Critical accounting estimates and judgements

Notes to the Financial Statements

(27) Critical accounting estimates and judgements (

(28) Change in accounting policies

Notes to the Financial Statements

[illegible] ([illegible])

(28) Change in accounting policies ([illegible])

([illegible]) [illegible]

[illegible]

The nature and reason for change in accounting policies	Impacted Financial Statement Line Item	Impacted amount 1 January 2018 Consolidated	Company
[illegible]	[illegible]	7,511,284	2,560,379
	[illegible]	(7,511,284)	(2,560,379)

[illegible]

Impacted Financial Statement Line Item	Impacted Amount 31 December 2018 [illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	([illegible])	([illegible])

Notes to the Financial Statements

(28) Change in accounting policies

Previous financial instrument standards			
Subjects	Measurement categories	Balance	
		50,974,323	

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

(28) Change in accounting policies ([illegible])

Notes to the Financial Statements

(28) Change in accounting policies

Notes to the Financial Statements

For the year ended 31 December 2018
(All amounts in RMB Yuan unless otherwise stated)

Category	Tax rate	Tax base
[illegible]	%	[illegible]
[illegible] ( )	% % %	[illegible]
[illegible]	%	[illegible]
[illegible]	%	[illegible]
[illegible]	%	[illegible]
[illegible]	% %	% [illegible]
[illegible]	[illegible]	[illegible]
[illegible]	% %	[illegible]

( ) [illegible]

[illegible] %

[illegible] % [illegible] % [illegible] %

Notes to the Financial Statements

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(1) Cash at bank and on hand

	31 December 2018	[illegible]
[illegible]	657,361	[illegible]
[illegible]	186,180,534	[illegible]
[illegible]	238,799	[illegible]
	187,076,694	[illegible]

[illegible]

(2) Accounts receivable

	31 December 2018	[illegible]
[illegible]	6,749,917	
[illegible]	318,519,503	[illegible]
[illegible]	325,269,420	[illegible]
[illegible]	(25,519,357)	([illegible])
	299,750,063	[illegible]

[illegible]

( ) [illegible]

	31 December 2018	[illegible]
[illegible]	261,000,854	[illegible]
[illegible]	51,396,190	[illegible]
[illegible]	12,862,881	[illegible]
[illegible]	9,495	[illegible]
	325,269,420	[illegible]

(2) Accounts receivable

	31 December 2018	
	Balance	Provision for bad debts
		Estimated credit loss during the
	Amount	

[illegible]

(3) Other receivables

	31 December 2018	[illegible]
[illegible]	20,712,000	[illegible]
[illegible]	7,461,889	[illegible]
[illegible]	17,970,291	[illegible]
[illegible]	7,709,142	[illegible]
[illegible]	8,443,740	[illegible]
	62,297,062	[illegible]
[illegible]	(4,245,481)	[illegible]
	58,051,581	[illegible]

( ) [illegible]

( ) [illegible]

[illegible]

[illegible]

Notes to the Financial Statements

[illegible]

[illegible]

[illegible]

(3) Other receivables ([illegible])

[illegible]

	The First Stage Expected Credit Loss within 12 months(Comprehensive) Balance	Provision for bad debt	The Third Stage Expected Credit loss within entire stage (Credit Losted) Balance	Provision for bad debt	Total Provision for bad debt
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]			[illegible]
[illegible]		([illegible])	([illegible])	([illegible])	([illegible])
[illegible]	60,140,947	3,035,451	2,156,115	1,210,030	4,245,481

[illegible]

	Balance	Expected Credit Loss rate within 12 months	Provision for bad debt
[illegible]			
[illegible]	[illegible]	[illegible]%	[illegible]
[illegible]	[illegible]	[illegible]%	[illegible]
[illegible]			
[illegible]	[illegible]	[illegible]%	[illegible]
[illegible]	[illegible]	[illegible]%	[illegible]
[illegible]	[illegible]	[illegible]%	[illegible]
	[illegible]		[illegible]

[illegible]

Notes to the Financial Statements
For the year ended 31 December 2018
(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(3) Other receivables ([illegible])

[illegible]

[illegible]

	Balance	Expected Credit Loss rate within survival period	Provision for bad deb
[illegible]	[illegible]	[illegible]%	[illegible]

[illegible]

[illegible]

[illegible]

(4) Advances to suppliers

	31 December 2018 Amount	%	[illegible]	%
[illegible]	16,576,535	100%	[illegible]	[illegible]%
[illegible]	75,304	—	[illegible]	
[illegible]	32,000	—		
	16,683,839	100%	[illegible]	[illegible]%

Notes to the Financial Statements

[illegible]

[illegible]

[illegible]

(5) Inventories

( ) [illegible]

	31 December 2018	[illegible]
[illegible]	14,933,448	[illegible]
[illegible]	3,305,013	[illegible]
[illegible] ( )	2,575,286	[illegible]
	20,813,747	[illegible]

[illegible]

[illegible])

( ) [illegible]

Project Name	Commencing Date	Completion Date	Total budgeted cost	Opening balance	Additions	Transfer to Cost of revenue (Note4(32))	Ending balance
[illegible]	[illegible]		[illegible]	[illegible]	[illegible]	([illegible])	

[illegible]

[illegible]

(5) Inventories ([illegible])

[illegible]

	[illegible]	[illegible]	[illegible]	[illegible]	31 December 2018
[illegible]	[illegible]	[illegible]	[illegible]	([illegible])	14,933,448
[illegible]	[illegible]	[illegible]	[illegible]	([illegible])	3,305,013
[illegible]	[illegible]		[illegible]	([illegible])	2,575,286
	[illegible]	[illegible]	[illegible]	([illegible])	20,813,747

(6) Current portion of non-current assets

	31 December 2018	[illegible]
[illegible] ( )	12,688,704	[illegible]

( ) [illegible]

(7) Other non-current financial assets/Available-for-sale financial assets

	31 December 2018	
	50,974,323	

Notes to the Financial Statements

For the year ended 31 December 2018
(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(8) Long-term equity investment ([illegible])

[illegible]

	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	31 December 2018
[illegible]	[illegible]			[illegible]		15,285,189
[illegible]	[illegible]		[illegible]	[illegible]		8,977,487
[illegible]	[illegible]			[illegible]		7,381,414
[illegible]	[illegible]		[illegible]	[illegible]		13,750,895
[illegible]	[illegible]			[illegible]		24,725,191
[illegible]	[illegible]		[illegible]	[illegible]	[illegible]	—
[illegible]	[illegible]			[illegible]	[illegible]	15,788,251
[illegible]		[illegible]		[illegible]		2,413,556
[illegible]		[illegible]				12,000,000
	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	100,321,983

Notes to the Financial Statements

(8) Long-term equity investment ([illegible])

[illegible]

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(8) Long-term equity investment ([illegible])

[illegible]

(9) Investment properties

	Properties and land use right
[illegible]	[illegible]

[illegible]

[illegible]

Notes to the Financial Statements

[illegible]

(10) Fixed assets

	Bulidings	Medical equitment	Motor vehicles	Electronic and other equitment	Total
[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]					
[illegible]					
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]				[illegible]
[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]				[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]					
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]				[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

( ) [illegible]

[illegible]

Notes to the Financial Statements

For the year ended 31 December 2018
(All amounts in RMB Yuan unless otherwise stated)

[illegible] ([illegible])

(10) Fixed assets ([illegible])

( ) ([illegible])

[illegible]

[illegible]

(11) Construction in progress

( ) [illegible]

Project name	31 December 2017	Increase in the year ended 31 December 2018	Transfer to fixed assets/long-term prepaid expenses	31 December 2018	Accumulative amount of capitalised borrowings costs	Including: Borrowings costs capitalised in theyear ended 31 December 2018	Capitalisation rate
[illegible] ( )	[illegible]	[illegible]		[illegible]	[illegible]	[illegible]	[illegible]%
[illegible]	[illegible]	[illegible]	([illegible])				
[illegible]	[illegible]	[illegible]		[illegible]			
[illegible]		[illegible]	([illegible])	[illegible]			
[illegible]	[illegible]	[illegible]		[illegible]			
[illegible]	[illegible]	[illegible]	([illegible])				
[illegible]	[illegible]	[illegible]	([illegible])				
[illegible]		[illegible]		[illegible]			
[illegible]		[illegible]		[illegible]			
[illegible]		[illegible]	([illegible])				
[illegible]	[illegible]	[illegible]	([illegible])	[illegible]			
	[illegible]	[illegible]	([illegible])	[illegible]	[illegible]	[illegible]	

[illegible]

( ) [illegible]

Notes to the Financial Statements

[illegible]

[illegible]

(12) Intangible assets

	Land use rights	Software	Contractual right to provide management service	Licences	Total
[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]		[illegible]
[illegible]	[illegible]	[illegible]			[illegible]
[illegible]		[illegible]			[illegible]
[illegible]	[illegible]	[illegible]	[illegible]		[illegible]
[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]		[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]			[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]		[illegible]

[illegible]

[illegible]

[illegible]

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(13) Goodwill

	[illegible]	[illegible]	31 December 2018
[illegible]			
[illegible]	[illegible]		8,533,389
[illegible]		[illegible]	7,784,850
[illegible]		[illegible]	9,271,800
[illegible]		[illegible]	2,239,355
[illegible]	[illegible]	[illegible]	27,829,394
[illegible]	([illegible])	([illegible])	(8,533,389)
	[illegible]	[illegible]	19,296,005

( ) [illegible]

	31 December 2018	[illegible]
[illegible]		
[illegible]	9,271,800	
[illegible]	7,784,850	
[illegible]	2,239,355	
[illegible]		
[illegible]	—	[illegible]
	19,296,005	[illegible]

[illegible]

Notes to the Financial Statements

[illegible]

(13) Goodwill [illegible]

(a) [illegible]

	Nanjing Yining Hospital	healthcare service Wenling Nanfang Hospital	Others
[illegible]	[illegible]% [illegible]%	[illegible]% [illegible]%	[illegible]% [illegible]%
[illegible]	[illegible]%	[illegible]%	[illegible]%
[illegible]	[illegible]% [illegible]%	[illegible]% [illegible]%	[illegible]% [illegible]%
[illegible]	[illegible]%	[illegible]%	[illegible]%

[illegible]

(b) [illegible]

(14) Long-term prepaid expense

	[illegible]	[illegible]	[illegible]	[illegible]	31 December 2018
[illegible]	[illegible]	[illegible]	[illegible]	([illegible])	143,890,269
[illegible]				([illegible])	496,400
	[illegible]	[illegible]	[illegible]	([illegible])	144,386,669

Notes to the Financial Statements

For the year ended 31 December 2018
(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(15) Deferred tax assets and deferred tax liabilities

[illegible]

	31 December 2018		[illegible]	
	Deductible temporary differences	Deferred tax assets	[illegible]	[illegible]
[illegible]	87,415,699	21,853,925	[illegible]	[illegible]
[illegible]	29,587,849	7,396,962	[illegible]	[illegible]
[illegible]	—	—	[illegible]	[illegible]
[illegible]	6,999,814	1,749,954		
[illegible]	6,245,972	1,561,493	[illegible]	[illegible]
[illegible]	4,925,394	1,231,349	[illegible]	[illegible]
[illegible]	126,654	31,664	[illegible]	

Notes to the Financial Statements

[illegible]

(15) Deferred tax assets and deferred tax liabilities ([illegible])

[illegible]

	31 December 2018 Taxable temporary differences	Deferred tax liabilities	[illegible]	[illegible]
[illegible]	58,830,476	14,707,619	[illegible]	[illegible]
[illegible]				
[illegible]		917,776		[illegible]
[illegible]		13,789,843		[illegible]
		14,707,619		[illegible]

[illegible]

	31 December 2018	[illegible]
[illegible]	—	[illegible]
[illegible]	121,875	[illegible]
	121,875	[illegible]

[illegible]

	31 December 2018	[illegible]
[illegible]	252	[illegible]
	16,339	[illegible]
[illegible]	105,284	
	121,875	[illegible]

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(16) Other non-current assets

	31 December 2018	[illegible]
[illegible]	—	[illegible]
[illegible]	3,420,001	[illegible]
[illegible]	4,097,899	[illegible]
[illegible]	—	[illegible]
	7,517,900	[illegible]

(17) Provision for assets impairment

	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	31 December 2018
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	25,519,357
[illegible]	[illegible]		[illegible]		[illegible]	[illegible]		4,245,481
[illegible]	[illegible]		[illegible]		[illegible]			8,533,389
	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	38,298,227

Notes to the Financial Statements

[illegible]

[illegible]

(18) Short-term borrowings

	31 December 2018	[illegible]
[illegible]	105,000,000	
[illegible]	40,000,000	[illegible]
	145,000,000	[illegible]

( ) [illegible]

[illegible] % % [illegible] %)

(19) Accounts payable

( ) [illegible]

	31 December 2018	[illegible]
[illegible]	43,099,493	[illegible]
[illegible]	3,971,590	[illegible]
[illegible]	836,832	[illegible]
[illegible]	25,470,222	[illegible]
[illegible]	50,357	[illegible]
[illegible]	216,223	[illegible]
	73,644,717	[illegible]

[illegible]

(20) Contract liability and Advance from customers

	31 December 2018	[illegible]
[illegible]	2,244,706	[illegible]

[illegible]

(21) Employee benefits payable

	31 December 2018	[illegible]
[illegible]	26,998,313	[illegible]
[illegible]	1,272,097	[illegible]
	28,270,410	[illegible]

Notes to the Financial Statements

(21) Employee benefits payable

					31 December 2018
[illegible]					
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	26,370,253
[illegible]			[illegible]	[illegible]	1,800
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	619,362
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	544,658
[illegible]	[illegible]		[illegible]	[illegible]	18,385
[illegible]	[illegible]			[illegible]	56,319
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	6,898
[illegible]			[illegible]	[illegible]	
	[illegible]	[illegible]	[illegible]	[illegible]	26,998,313

[illegible]

(21) Employee benefits payable

Notes to the Financial Statements

[illegible]

(23) Other payables

	31 December 2018	[illegible]
[illegible]	55,265,308	[illegible]
[illegible]	23,501,353	[illegible]
[illegible]	3,410,000	[illegible]
[illegible]	6,657,029	[illegible]
[illegible]	6,000,000	[illegible]
[illegible]	3,743,045	[illegible]
[illegible]	21,910,000	[illegible]
[illegible]	—	[illegible]
[illegible]	1,554,541	[illegible]
[illegible]	7,766,712	[illegible]
	129,807,988	[illegible]

[illegible]

(24) Current portion of non-current liabilities

	31 December 2018	[illegible]
[illegible]	40,000,000	[illegible]
[illegible]	23,757,304	[illegible]
	63,757,304	[illegible]

[illegible]

(25) Long-term borrowings

	31 December 2018	[illegible]
[illegible]	80,000,000	[illegible]
[illegible]	(40,000,000)	
	40,000,000	[illegible]

[illegible]

(26) Long-term payable

	31 December 2018	[illegible]
[illegible] ( )	12,688,704	[illegible]
[illegible]	97,713,800	[illegible]
	110,402,504	[illegible]
[illegible]	(23,757,304)	([illegible])
	86,645,200	[illegible]

( ) [illegible]

Notes to the Financial Statements

(27) Deferred income

	31 December 2018	[illegible]
[illegible]	10,253,059	–

[illegible]	[illegible]	[illegible]	[illegible]	31 December 2018	Related to assets/income
[illegible]	–	–	[illegible]	10,253,059	Related to assets

(28) Share capital

	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	

Notes to the Financial Statements

(31) Retained earning

	Year ended 31 December	
	2018	[illegible]
[illegible]	146,840,254	[illegible]
[illegible]	(164,301)	
[illegible]	146,675,953	[illegible]
[illegible]	80,595,677	[illegible]
[illegible]	(6,271,022)	[illegible]
[illegible]	(10,956,000)	[illegible]
[illegible]	210,044,608	[illegible]

Notes to the Financial Statements

For the year ended 31 December 2018
(All amounts in RMB Yuan unless otherwise stated)

[illegible] ([illegible])

(32) Revenue and cost of sales ([illegible])

( ) [illegible]

	Year ended 31 December 2018 Revenue	Cost	[illegible]	[illegible]
[illegible]	167,103,194	140,329,511	[illegible]	[illegible]
[illegible]	539,548,284	331,883,344	[illegible]	[illegible]
[illegible]	19,747,723	12,816,061	[illegible]	[illegible]
	726,399,201	485,028,916	[illegible]	[illegible]

( ) [illegible]

	Year ended 31 December 2018 Revenue	Cost	[illegible]	[illegible]
[illegible]	9,471,045	7,260,685	[illegible]	[illegible]
[illegible]	7,568,944	—	[illegible]	
[illegible]	2,532,698	1,440,035	[illegible]	[illegible]
	19,572,687	8,700,720	[illegible]	[illegible]

(33) Taxes and surcharges

	Year ended 31 December 2018 2018	[illegible]	[illegible]
[illegible]	845,222	[illegible]	[illegible]
[illegible]	4,139,967	[illegible]	[illegible]
[illegible]	134,982	[illegible]	[illegible]
[illegible]	57,691	[illegible]	[illegible]
[illegible]	542,339	[illegible]	
	5,720,201	[illegible]	

Notes to the Financial Statements

[illegible]

[illegible]

[illegible]

(34) Expenses by nature

[illegible]

	Year ended 31 December	
	2018	[illegible]
[illegible]	221,649,507	[illegible]
[illegible]	179,200,817	[illegible]
[illegible]	7,260,685	[illegible]
[illegible]	28,914,368	[illegible]
[illegible]	9,933,744	[illegible]
[illegible]	24,113,944	[illegible]
[illegible]	32,065,307	[illegible]
[illegible]	25,331,355	[illegible]
[illegible]	14,021,346	[illegible]
[illegible]	4,049,315	[illegible]
[illegible]	14,092,852	[illegible]
[illegible]	7,497,157	[illegible]
[illegible]		
[illegible]	3,000,000	[illegible]
[illegible]	70,096	
[illegible]	2,637,078	[illegible]
[illegible]	5,930,695	[illegible]
[illegible]	6,047,780	[illegible]
[illegible]	2,372,415	[illegible]
[illegible]	14,417,462	[illegible]
	602,605,923	[illegible]

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(35) Finance expenses-net

	Year ended 31 December	
	2018	[illegible]
[illegible]	(4,073,649)	[illegible]
[illegible]	(3,682,615)	[illegible]
[illegible]	12,684,236	[illegible]
[illegible]	(3,833,934)	[illegible]

Notes to the Financial Statements

(37) Credit impairment losses

	Year ended 31 December 2018

[illegible]

(39) Other gains

	Year ended 31 December 2018	[illegible]	[illegible]
[illegible] ( )	2,010,000	[illegible]	[illegible]
[illegible] ( )	3,908,500	[illegible]	[illegible]
[illegible]	2,094,077	[illegible]	[illegible]
[illegible]	525,658		[illegible]
	8,538,235	[illegible]	

( ) [illegible]

( ) [illegible]

(40) Non-operating income

	Year ended 31 December 2018	[illegible]
[illegible]	6,713,886	[illegible]
[illegible]	468,186	[illegible]
	7,182,072	[illegible]

Notes to the Financial Statements

[illegible]

[illegible]

(41) Non-operating expenses

	Year ended 31 December 2018	[illegible]
[illegible]	—	[illegible]
[illegible]	5,254,412	[illegible]
[illegible]	292,800	[illegible]
[illegible]	494,763	[illegible]
	6,041,975	[illegible]

(42) Income tax expenses

	Year ended 31 December 2018	[illegible]
[illegible]	39,910,885	[illegible]
[illegible]	(7,969,845)	([illegible])
	31,941,040	[illegible]

[illegible]

	Year ended 31 December 2018	[illegible]
[illegible]	106,910,268	[illegible]
[illegible] %	26,727,567	[illegible]
[illegible]	3,898,294	[illegible]
[illegible]	2,553,569	[illegible]
[illegible]	(850,617)	
[illegible]	—	([illegible])
[illegible]	26,321	[illegible]
[illegible]	—	[illegible]
[illegible]	(414,094)	([illegible])
[illegible]	31,941,040	[illegible]

Notes to the Financial Statements

[illegible]

[illegible]

[illegible]

(44) Supplementary information to the statement of cash flows

[illegible]

[illegible]

	Year ended 31 December 2018	[illegible]
[illegible]	74,969,228	[illegible]
[illegible]	4,823,557	[illegible]
[illegible]	18,695,980	
[illegible]	28,914,368	[illegible]
[illegible]	9,933,744	[illegible]
[illegible]	24,113,944	[illegible]
[illegible]	1,420,551	[illegible]
[illegible]	—	[illegible]
[illegible]	6,604,738	[illegible]
[illegible]	8,302,493	[illegible]
[illegible]	(303,792)	([illegible])
[illegible]	(7,104,335)	([illegible])
[illegible]	(865,510)	([illegible])
[illegible]	3,284,122	[illegible]
[illegible]	2,372,415	[illegible]
[illegible]	(84,326,090)	([illegible])
[illegible]	(24,314,885)	([illegible])
[illegible]	66,520,528	[illegible]

[illegible]

[illegible]

(44) Supplementary information to the statement of cash flows ([illegible])

	Year ended 31 December 2018	
	187,066,694	[illegible]
	(237,538,659)	[illegible]
	(50,471,965)	[illegible]

	2018
	18,290,000
	1,580,000
	—
	6,000,000
	10,710,000
	(769,804)
	(301,276)
	(468,528)
	17,520,196

	31 December 2018	
	657,361	[illegible]
	186,170,534	[illegible]
	238,799	[illegible]
	187,066,694	[illegible]

Notes to the Financial Statements

(1) Business combination involving enterprises not under common control

Acquiree	Date of addition	Purchase consideration	% of equity interest	Date of acquisition	Basis for acquisition	Revenue of the acquiree from the date

(1) Business combination involving enterprises not under common control

(1) Business combination involving enterprises not under common control

Notes to the Financial Statements

(1) Business combination involving enterprises not under common control

(1) Business combination involving enterprises not under common control ([illegible])

[illegible]

Notes to the Financial Statements

(1) Interests in subsidiaries

[illegible] ([illegible])

(1) Interests in subsidiaries ([illegible])

([illegible]) [illegible]

	31 December 2018	[illegible]
[illegible]	10,067,491	[illegible]
[illegible]	8,424,991	[illegible]
[illegible]	13,116,462	[illegible]
[illegible]	13,612,308	[illegible]
[illegible]	10,533,224	[illegible]
[illegible]	2,779,948	[illegible]
[illegible]	25,743,404	[illegible]
	84,277,828	[illegible]

([illegible]) [illegible]

[illegible]	Shareholding % of non-controlling shareholders	Net profit or loss attributable to non-controlling shareholders for year ended 31 December 2018	Non-controlling interests as at 31 December 2018
[illegible]	25%	(998,478)	13,612,308
[illegible]	48%		

Notes to the Financial Statements

[illegible]

[illegible]

[illegible]

(1) Interests in subsidiaries [illegible]

[illegible]

[illegible]

	31 December 2018					
	Current assets	Non-current assets	Total assets	Current liabilities	Non-current liabilities	Total liabilities
[illegible]	16,773,329	165,362,467	182,135,796	117,724,378	9,308,166	127,032,544
[illegible]	11,562,794	29,341,925	40,904,719	14,349,851	—	14,349,851
[illegible]	37,742,817	31,388,018	69,130,835	16,241,445	—	16,241,445
[illegible]	4,054,503	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(1) Interests in subsidiaries [illegible]

[illegible]

Notes to the Financial Statements

[illegible]

[illegible]

[illegible]

(2) Interests in associates

[illegible]

	Principal Place of Business	Registry Place	Bustiness Nature	Is it Strategic to Group Business	Shareholding ratio Direct	Shareholding ratio Indirect
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]%
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		[illegible]%

[illegible]

[illegible]

	Year ended 31 December 2018 Chengdu Yining	Year ended 31 December 2018 Shanxi Shanda
[illegible]	9,758,005	30,077,967
[illegible]	54,414,823	47,166,506
[illegible]	64,172,828	77,244,473
[illegible]	19,738,345	9,808,123
[illegible]	44,434,483	67,436,350
[illegible]	10,664,276	20,230,905
[illegible]		
[illegible]	5,024,000	4,494,286
[illegible]	99,975	—
[illegible]	15,788,251	24,725,191

Notes to the Financial Statements

For the year ended 31 December 2018
(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(2) Interests in associates ([illegible])

[illegible]

	Year ended 31 December 2018	
	Chengdu Yining	Shanxi Shanda
[illegible]	1,528,541	16,307,931
[illegible]	(11,136,779)	(1,926,430)

( ) [illegible]

[illegible]

[illegible] ( )

	Year ended 31 December	
	2018	[illegible]
[illegible]	59,808,541	[illegible]
[illegible]		
[illegible] ( )	(6,778,513)	(–)
[illegible]	(6,778,513)	(–)

( ) [illegible]

Notes to the Financial Statements

	Healthcare and related service	Property investment and development	Total

Notes to the Financial Statements

For the year ended 31 December 2018
(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(1) General information of the Company

[illegible]

(2) The information of the subsidiaries

[illegible]

(3) The information of other related party

[illegible]

[illegible]

(4) Related party transactions

[illegible]

[illegible]

	Year ended 31 December	
	2018	[illegible]
[illegible]	3,000,000	[illegible]
[illegible]	373,624	[illegible]
[illegible]	548,306	[illegible]
	3,921,930	[illegible]

[illegible]

	Year ended 31 December	
	2018	[illegible]
[illegible]	1,037,328	[illegible]
[illegible]	—	[illegible]
	1,037,328	[illegible]

Notes to the Financial Statements

For the year ended 31 December 2018
(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(4) Related party transactions ([illegible])

[illegible]

	Year ended 31 December 2018	[illegible]
[illegible]	—	[illegible]
[illegible]	1,312,205	[illegible]
[illegible]	179,057	[illegible]
[illegible]	—	[illegible]
[illegible]	2,665,101	[illegible]
[illegible]	—	[illegible]
[illegible]	911,600	
[illegible]	9,319,230	
	14,387,193	[illegible]

[illegible]

	Year ended 31 December 2018	[illegible]
[illegible]	90,226	
[illegible]	—	[illegible]
[illegible]	—	[illegible]
	90,226	[illegible]

[illegible]

	Year ended 31 December 2018	[illegible]
[illegible]	—	[illegible]

(4) Related party transactions ([illegible])

( ) [illegible]

	Year ended 31 December 2018	[illegible]
[illegible]	4,163,800	[illegible]
[illegible]	459,935	[illegible]
	4,623,735	[illegible]

( ) [illegible]

	Year ended 31 December 2018	[illegible]
[illegible]	185,000,000	[illegible]
[illegible]	—	[illegible]
	185,000,000	[illegible]

( ) [illegible]

	Year ended 31 December 2018	[illegible]
[illegible]	1,730,715	[illegible]

(5) Balances with related parties

	31 December 2018		
	Balances	Provision for bad debts	

(5) Balances with related parties ([illegible])

	31 December 2018	[illegible]
[illegible]	86,645,200	
[illegible]	124,453	[illegible]
[illegible]	—	[illegible]
[illegible]	4,274,945	[illegible]
[illegible]	2,159,583	
[illegible]	14,700,000	
[illegible]	3,015,289	
[illegible]	500,000	
[illegible]	2,137,083	
[illegible]	—	—
	26,911,353	[illegible]

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(6) Key management compensation

(i) [illegible]

[illegible]	Fees	Salaries	Contributions to pension plans	Bonus	Other staff welfare expenses	Total
Executive directors(i)						
[illegible]	—	396,000	21,974	74,951	33,784	526,709
[illegible]	—	324,000	21,974	74,951	33,784	454,709
[illegible]	—	166,100	21,974	68,628	33,064	289,766
Non- Executive directors(i)						
[illegible]	—	—	—	—	—	—
[illegible]	—	—	—	—	—	—
Independent directors						
[illegible]	70,000	—	—	—	—	70,000
[illegible]	70,000	—	—	—	—	70,000
[illegible]	70,000	—	—	—	—	70,000
Supervisiors						
[illegible]	—	—	—	—	—	—
[illegible]	—	33,636	9,996	65,460	16,000	125,092
[illegible]	—	—	—	—	—	—
[illegible]	—	—	—	—	—	—
[illegible]	—	—	—	—	—	—
[illegible]	210,000	919,736	75,918	283,990	116,632	1,606,276

[illegible]

(6) Key management compensation ([illegible])

( ) [illegible]

[illegible]	Fees	Salaries	Contributions to pension plans	Bonus	Other staff welfare expenses	Total
Executive directors(i)						
[illegible]	—	396,435	21,722	69,416	33,530	521,103
[illegible]	—	324,435	21,722	69,416	33,530	449,103
[illegible]	—	181,635	21,722	69,416	29,210	301,983
Non- Executive directors(i)						
[illegible]	—	—	—	—	—	—
[illegible]	—	—	—	—	—	—
Independent directors						
[illegible]	70,000	—	—	—	—	70,000
[illegible]	70,000	—	—	—	—	70,000
[illegible]	70,000	—	—	—	—	70,000
Supervisiors						
[illegible]	—	120,435	—	69,013	—	189,448
[illegible]	—	47,829	9,408	52,067	10,566	119,870
[illegible]	—	—	—	—	—	—
[illegible]	—	—	—	—	—	—
[illegible]	—	—	—	—	—	—
[illegible]	210,000	1,070,769	74,574	329,328	106,836	1,791,507

(a) The Restricted Shares Scheme I

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

(a) The Restricted Shares Scheme I

(b) The Restricted Shares Scheme II

(b) The Restricted Shares Scheme II (

Notes to the Financial Statements

For the year ended 31 December 2018
(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(1) Capital commitments

[illegible]

	31 December 2018	[illegible]
[illegible]	146,163,230	[illegible]
[illegible]	698,000	[illegible]
	146,861,230	[illegible]

(2) Operating lease commitments

[illegible]

	31 December 2018	[illegible]
[illegible]	18,222,418	[illegible]
[illegible]	23,233,247	[illegible]
[illegible]	25,196,169	[illegible]
[illegible]	208,298,211	[illegible]
	274,950,045	[illegible]

(3) External investment commitments

[illegible]

11 [illegible]

(1) [illegible]

(2) [illegible] % [illegible]

Notes to the Financial Statements

[illegible]

(1) Market risk

[illegible]

	31 December 2018		
	HKD	USD	Total
[illegible]	34,063,970	15,166,718	49,230,688

	[illegible]		
	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]

[illegible] % [illegible]

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

(1) Market risk

(2) Credit risk

(2) Credit risk ([illegible])

[illegible]

[illegible]

(3) Liquidity risk

	31 December 2018				
	Within 1 year	1 to 2 years	2 to 5 years	Over 5 years	Total
[illegible]	73,644,717	—	—	—	73,644,717
[illegible]	130,587,030	206,950	—	—	130,793,980
[illegible]	23,757,304	6,377,600	23,220,900	118,035,800	171,391,604
[illegible]	191,380,007	41,905,205	—	—	233,285,212
	419,369,058	48,489,755	23,220,900	118,035,800	609,115,513

[illegible]

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

(3) Liquidity risk (

Notes to the Financial Statements

(1) Assets and liabilities measured at fair value on a recurring basis

	31 December 2018		
	Level 1	Level 2	Level 3

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

(1) Assets and liabilities measured at fair value on a recurring basis ( )

Notes to the Financial Statements

[illegible]

[illegible]

[illegible]

(1) Accounts receivable

	31 December 2018	[illegible]
[illegible]	118,533,802	[illegible]
[illegible]	(10,356,640)	([illegible])
	108,177,162	[illegible]

[illegible]

	31 December 2018	[illegible]
[illegible]	90,659,674	[illegible]
[illegible]	21,053,851	[illegible]
[illegible]	6,814,718	[illegible]
[illegible]	5,559	[illegible]
	118,533,802	[illegible]

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

[illegible] ([illegible])

(1) Accounts receivable ([illegible])

( ) [illegible]

( ) [illegible]

( ) [illegible]

	31 December 2018		
	Balance	Provision for bad debts	
	Amount	Estimated credit loss during the survival period	Amount
[illegible]	6,493,620	1%	64,936
[illegible]	48,710,059	5%	2,435,503
[illegible]	35,455,995	6%	2,127,360
[illegible]	21,053,851	11%	2,315,923
[illegible]	6,814,718	50%	3,407,359
[illegible]	5,559	100%	5,559
[illegible]	118,533,802	9%	10,356,640

( ) [illegible]

( ) [illegible]

Notes to the Financial Statements

[illegible]

(2) Other receivables

	31 December 2018	[illegible]
[illegible]	552,370,656	[illegible]
[illegible]	—	[illegible]
[illegible]	2,866,522	[illegible]
[illegible]	704,200	[illegible]
[illegible]	966,927	[illegible]
	556,908,305	[illegible]
[illegible]	(2,135,598)	[illegible]
	554,772,707	[illegible]

[illegible]

	The First Stage Expected Credit Loss within 12 months(Comprehensive)		The Third Stage Expected Credit loss within entire stage (Credit Losted)		Total
	Balance	Provision for bad debt	Balance	Provision for bad debt	Provision for bad debt
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]			[illegible]
[illegible]			[illegible]	[illegible]	[illegible]
31 December 2018	554,752,190	925,568	2,156,115	1,210,030	2,135,598

Notes to the Financial Statements

For the year ended 31 December 2018
(All amounts in RMB Yuan unless otherwise stated)

[illegible] ([illegible])

(2) Other receivables ([illegible])

([illegible]) [illegible] ([illegible])

([illegible]) [illegible]

	Balance	Expected Credit Loss rate within 12 months	Provision for bad debt
[illegible]			
[illegible]	[illegible]	[illegible]%	[illegible]
[illegible]			
[illegible]	[illegible]	[illegible]%	[illegible]
[illegible]			
[illegible]	[illegible]		
[illegible]	[illegible]	[illegible]%	[illegible]
[illegible]	[illegible]	[illegible]%	[illegible]
	[illegible]		[illegible]

([illegible]) [illegible]

([illegible]) [illegible]

	Balance	Expected Credit Loss rate within survival period	Provision for bad deb
[illegible]			
[illegible])	[illegible]	[illegible]%	[illegible]

[illegible]) [illegible]

Notes to the Financial Statements

(2) Other receivables

(3) Long-term equity investment

	31 December 2018	
	139,727,432	

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

(3) Long-term equity investment

Notes to the Financial Statements

(4) Fixed assets

(5) Construction in progress

		Increase in the year ended 31 December 2018		31 December 2018			
[illegible]	[illegible]	8,838,609	[illegible]	4,508,592			

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(6) Intangible assets

	Land use rights	Software	Contractual right to provide management service	Total
[illegible]				
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]		[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]				
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]				
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Notes to the Financial Statements

[illegible]

(7) Provision for assets impairment

	[illegible]	Change in accounting policy	[illegible]	Addition	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	514,163	[illegible]	5,075,345		[illegible]	[illegible]
[illegible]	[illegible]	—	[illegible]	112,858	[illegible]		[illegible]
	[illegible]	514,163	[illegible]	5,188,203	[illegible]	[illegible]	[illegible]

(8) Capital surplus

	[illegible]	[illegible]	[illegible]	30 June 2018
[illegible]		[illegible]		781,870,038
[illegible]				—
[illegible]	[illegible]	[illegible]	[illegible]	6,245,972
[illegible]	[illegible]			40,815,879
	[illegible]	[illegible]	[illegible]	828,931,889

Notes to the Financial Statements

For the year ended 31 December 2018
(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(9) Retained earning

	Year ended 31 December 2018	[illegible]
[illegible]	137,084,775	[illegible]
[illegible]	345,120	
[illegible]	137,429,895	[illegible]
[illegible]	62,710,220	[illegible]
[illegible]	(6,271,022)	([illegible])
[illegible]	(10,956,000)	([illegible])
[illegible]	182,913,093	[illegible]

[illegible]

[illegible]

Notes to the Financial Statements

[illegible]

[illegible]

(10) Revenue and cost of sales

	Year ended 31 December 2018 Revenue	Cost	[illegible]	[illegible]
[illegible]	353,371,156	230,191,852	[illegible]	[illegible]
[illegible]	795,683	—	[illegible]	[illegible]
	354,166,839	230,191,852	[illegible]	[illegible]

[illegible]

	Year ended 31 December 2018 Revenue	Cost	[illegible]	[illegible]
[illegible]	95,855,967	81,667,345	[illegible]	[illegible]
[illegible]	244,567,918	137,943,217	[illegible]	[illegible]
[illegible]	12,947,271	10,581,290	[illegible]	[illegible]
	353,371,156	230,191,852	[illegible]	[illegible]

[illegible]

	Year ended 31 December 2018 Revenue	Cost	[illegible]	[illegible]
[illegible]	97,199	—		
[illegible]	698,484	—	[illegible]	
	795,683	—	[illegible]	

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(11) Financial expenses-net

	Year ended 31 December	
	2018	[illegible]
		[illegible]
[illegible]	(4,073,649)	[illegible]
[illegible]	(1,955,764)	[illegible]
[illegible]	5,296,137	[illegible]
[illegible]	—	[illegible]
[illegible]	5,510,700	[illegible]
[illegible]	420,685	[illegible]
	5,198,109	[illegible]

( ) [illegible]

Notes to the Financial Statements

[illegible]

[illegible]

(12) Expenses by nature

[illegible]

	Year ended 31 December	
	2018	[illegible]
[illegible]	109,340,101	[illegible]
[illegible]	103,704,494	[illegible]
[illegible]	16,032,342	[illegible]
[illegible]	5,797,361	[illegible]
[illegible]	4,709,375	[illegible]
[illegible]	2,245,763	[illegible]
[illegible]	8,733,336	[illegible]
[illegible]	5,400,825	[illegible]
[illegible]	1,107,951	[illegible]
[illegible]	4,479,612	[illegible]
[illegible]	6,494,091	[illegible]
[illegible]		
[illegible]	3,000,000	[illegible]
[illegible]	70,096	
[illegible]	1,419,359	
[illegible]	[illegible]	[illegible]

Notes to the Financial Statements

For the year ended 31 December 2018

(All amounts in RMB Yuan unless otherwise stated)

[illegible]

(13) Credit impairment losses

	Year ended 31 December	
	2018	[illegible]
[illegible]	5,075,345	
[illegible]	(154,185)	
[illegible]	4,921,160	

(14) Investment income

	Year ended 31 December	
	2018	[illegible]
		[illegible]
[illegible]	18,000,000	[illegible]
[illegible]	(689,990)	[illegible]
[illegible]	—	[illegible]
[illegible]	490,898	[illegible]
	17,800,908	[illegible]

Notes to the Financial Statements

[illegible]

(15) Income tax expenses

	Year ended 31 December 2018	[illegible]
[illegible]	17,267,982	[illegible]
[illegible]	(2,410,323)	[illegible]
	14,857,659	[illegible]

[illegible]

	Year ended 31 December 2018	[illegible]
[illegible]	77,567,879	[illegible]
[illegible] %	19,391,970	[illegible]
[illegible]	584,775	[illegible]
[illegible]	(850,617)	
[illegible]	231,531	[illegible]
[illegible]	(4,500,000)	[illegible]
[illegible]	14,857,659	[illegible]

Definitions

（北京怡寧醫院有限公司） %

（蒼南康寧醫院有限公司）

（成都怡寧醫院有限公司 （成都仁一醫院有限公司）） %

（淳安黃鋒康恩醫院）

Definitions

Definitions

[illegible] （淮南康寧醫院有限公司） [illegible] % [illegible]

[illegible] （廊坊怡寧醫院有限公司 [illegible] （廊坊市怡寧醫院管理有限公司)) [illegible]

[illegible]

[illegible] （臨海康寧醫院有限公司） [illegible]

[illegible] （台州市路橋慈寧醫院有限公司, [illegible] （台州市路橋怡寧醫院有限公司）） [illegible]

[illegible]

[illegible]

[illegible] （南京怡寧醫院有限公司） [illegible]

[illegible]

[illegible]

Definitions

(深圳怡寧醫院

(深圳市怡寧醫院有限公司))

(四會康寧醫院有限公司)

(台州康寧醫院有限公司)

(溫嶺南方精神疾病專科醫院有限公司)

Definitions

[illegible]	[illegible] (温州慈寧醫院有限公司) [illegible]
[illegible]	[illegible] (温州國大投資有限公司) [illegible]
[illegible]	[illegible] (燕郊輔仁中西醫結合醫院) [illegible] (廊坊三河燕郊輔仁醫院 [illegible] (燕郊輔仁中西醫結合醫院)) [illegible]
[illegible]	[illegible] (樂清康寧醫院有限公司) [illegible]
[illegible]	[illegible] (永嘉康寧醫院有限公司) [illegible]
%[illegible]	[illegible]

溫州康寧醫院股份有限公司
Wenzhou Kangning Hospital Co., Ltd.